GSK: Phil Dormitzer M.D., Ph.D
Phil Dormitzer M.D., Ph.D., has joined GSK as Global Head of Vaccines R&D.
Dormitzer, who started in the role on December 3, was previously Vice President and Chief Scientific Officer, RNA and Viral Vaccines, at Pfizer: providing scientific leadership for the development of the Pfizer/BioNTech COVID-19 vaccine. He headed up the Viral Vaccines R&D portfolio, which included the company’s maternal and older adult respiratory syncytial virus (RSV) vaccine candidates (based on their stabilised prefusion F-based technology), which are now in Phase III clinical trials. He was also responsible for Pfizer’s RNA-based influenza vaccine candidate, being developed in collaboration with BioNTech SE.
Prior to this, Dormitzer held roles of increasing responsibility with Novartis Vaccines and Diagnostics, including leading the research component of the company’s response to the H1N1 influenza pandemic that supported the development of three licensed vaccines and latterly as Head of US Vaccines Research.
Dormitzer will report to Dr Hal Barron, Chief Scientific Officer and President R&D, and join GSK’s R&D Leadership Team, and the Vaccines Leadership Team. Phil will be based in Greater Boston, Massachusetts, US.